BMS Expands Tempus Data Deal Through 2031, Becomes Top Oncology Data Licensor
TEM sits 55% above its 52-week low of $40.77.
Summary
Tempus signed a multi-year agreement under which Bristol Myers Squibb will license its multimodal oncology data through 2031, and BMS becomes one of Tempus's largest licensors of de-identified oncology data. BMS also gets access to Tempus's Lens Platform, an AI environment connected to GPU infrastructure for training models on that data. No dollar value or revenue contribution was disclosed, so the immediate financial impact is unquantified. The deal deepens an existing relationship that already covered clinical trial design in oncology and neuroscience, and it lands as Tempus works through its $1.5B all-stock acquisition of Personalis, with the shareholder vote set for November 30, 2026. For BMS the agreement is a modest data-access expansion; for Tempus, a large pharma licensor validating its data asset matters more to the equity story.
At the time of this announcement, TEM was trading at $63.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.5B. The 52-week trading range was $40.77 to $93.38. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.